Technical Analysis for IFRX - InflaRx N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 1.71 | -1.72% | -0.03 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 200 DMA | Bullish | -1.72% | |
| Above Upper BB | Strength | -1.72% | |
| Upper Bollinger Band Touch | Strength | -1.72% | |
| 20 DMA Support | Bullish | 2.40% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 2.40% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 4 hours ago |
| Down 5% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 3% | about 9 hours ago |
| 2x Volume Pace | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/08/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Clinical Development Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.35 |
| 52 Week Low | 1.14 |
| Average Volume | 171,184 |
| 200-Day Moving Average | 1.70 |
| 50-Day Moving Average | 1.47 |
| 20-Day Moving Average | 1.59 |
| 10-Day Moving Average | 1.60 |
| Average True Range | 0.13 |
| RSI (14) | 61.24 |
| ADX | 36.56 |
| +DI | 28.66 |
| -DI | 8.88 |
| Chandelier Exit (Long, 3 ATRs) | 1.44 |
| Chandelier Exit (Short, 3 ATRs) | 1.77 |
| Upper Bollinger Bands | 1.73 |
| Lower Bollinger Band | 1.45 |
| Percent B (%b) | 0.94 |
| BandWidth | 17.49 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0145 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.94 | ||||
| Resistance 3 (R3) | 1.93 | 1.85 | 1.90 | ||
| Resistance 2 (R2) | 1.85 | 1.79 | 1.85 | 1.89 | |
| Resistance 1 (R1) | 1.78 | 1.76 | 1.74 | 1.79 | 1.87 |
| Pivot Point | 1.70 | 1.70 | 1.68 | 1.70 | 1.70 |
| Support 1 (S1) | 1.63 | 1.64 | 1.59 | 1.63 | 1.55 |
| Support 2 (S2) | 1.55 | 1.61 | 1.55 | 1.53 | |
| Support 3 (S3) | 1.48 | 1.55 | 1.52 | ||
| Support 4 (S4) | 1.48 |
